Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -20.59% and -44.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates

Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

Gilead Sciences

Galapagos

Intercept Pharma

PTC Therapeutics

A growing number of Covid-19 cases could frustrate biotech companies' efforts to enroll patients in clinical studies, an analyst said Tuesday.

The Surprising Impact Coronavirus Will Have On Biotech Companies

Norwood, MA, March  10, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the appointment of Pete Salzmann, M.D., MBA, to its Board of Directors.

Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline

If Corbus announces positive results this summer from two late-stage clinical trials, the current stock price could be a steal. But it's not for the faint of heart.

Is Corbus Pharmaceuticals Stock On Sale at This Price?

Norwood, MA, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the closing of its public offering of 7,666,667 shares of its common stock, including 1,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.

Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Norwood, MA, Feb.  07, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $6.00 per share, for a total public offering size of approximately $40 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Corbus. The offering is expected to close on or about February 11, 2020, subject to customary closing conditions.

Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Norwood, MA, Feb.  06, 2020  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it plans to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Arena Pharmaceuticals

Cara Therapeutics

Cronos Group

Greenlane Holdings

GW Pharmaceuticals

Marrone Bio Innovations

New Age Beverages

Intec Parent

OrganiGram Holdings Inc.

Psychemedics

SNDL Inc.

Tilray Brands

Therapix Biosciences

Village Farms International

Zynerba Pharmaceuticals

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Top Marijuana Stocks on the NASDAQ

Both of these biotechs could become smash hits, but which is better?

Better Buy: Cara Therapeutics vs. Corbus Pharmaceuticals

- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET

Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

Norwood, MA, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of patient enrollment in the Phase 2b study evaluating the efficacy and safety of lenabasum for the treatment of cystic fibrosis (CF). The Company expects to report topline data from this study in the summer of 2020. Lenabasum has Orphan Drug Designation and Fast Track status for treatment of CF.

Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

- Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST -

Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2019 Results - Earnings Call Transcript

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 49.71%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Tops Revenue Estimates

It’s full steam ahead with a slate of late-stage clinical trial results expected in 2020. However, Corbus just release its third quarter results, and the financial picture looks bleak.

Is Corbus Pharmaceuticals Stock a Buy?

Better Buy:  GW Pharmaceuticals vs.  Corbus Pharmaceuticals

Norwood, MA, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced its financial results for the third quarter ended September 30, 2019. The Company also provided an update on its corporate progress, clinical status and financial position.

Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

Corbus is developing endocannabinoid-based therapeutics for the treatment of autoimmune, orphan, and fibrotic skin and lung diseases.

Corbus Pharmaceuticals And Lenabasum In Systemic Sclerosis

COO of Corbus Pharmaceuticals Holdings Inc (30-Year Financial, Insider Trades) Robert Paul Discordia (insider trades) bought 15,000 shares of CRBP on 08/12/2019 at an average price of $5.86 a share.

Corbus Pharmaceuticals Holdings Inc (CRBP) COO Robert Paul Discordia Bought $87,900 of Shares

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2019 Results - Earnings Call Transcript

A licensing agreement enabled the clinical-stage biotech to report a big jump in revenue and a nice profit in Q2.

What You'll Want to Know About Corbus Pharmaceuticals' Q2 Results

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Q2 Earnings and Revenues Beat Estimates

News for Corbus Pharmaceuticals Holdings Stock (CRBP)